Abstract 2127P
Background
Yoga has gained more attention worldwide in the last decade and shown the potential to improve physiological and psychological health in various disease conditions. Studies on breast cancer (BC) survivors showed mild to moderate effects within one-month to six-month on various parameters. Cancer treatment-related side effects are often related with functional as well as symptomatic scales. Therefore, we have conducted a randomized control study to find out the effect of long-term yogic intervention on symptom and functional scale in patients undergoing treatment.
Methods
This study was approved by the institutional ethics committee. The current study consisted of 96 BC stage II/III patients receiving cancer treatments who were randomly divided into two groups: Group-I (non-yoga) and Group-II (yoga). Group-II was advised to perform yoga 5 days per week for 48 weeks and was monitored regularly by video or phone calls. At different time points (T0 (baseline), T1 (16th week), T2 (32nd week), and T3 (48th week), we collected the breast cancer specific questionnaire (EORTC-BR23), which consisted of various functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and symptomatic scales (systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss), and compared them between groups as well as within group.
Results
Out of 96 total patients, 82 were analyzed for T0-T3 (40 in group-I and 42 in group-II). In groups I and II, the mean age was 47.67±11.68 and 43.11±9.39, respectively. Yogic intervention resulted in a significant improvement in arm symptoms and side effects from T0 to T3 (p<0.001) and T1 to T3 (p<0.01) in group II, while group I also improved from T0 to T3 (p<0.05). The most significant difference was observed in Group-I (T0) vs. Group-II (T3). There was no significant difference observed in upset by hair loss, body image, breast symptoms, or future perspective.
Conclusions
The duration of yoga positively correlated with the systematic therapy side effects and improved their arm symptoms. This suggested that yogic intervention during therapy could be an effective complementary therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06